|
Financial toxicity in prostate cancer survivors: A national cross-sectional assessment of subjective financial burden
|
November 13, 2022
|
PC3I Authors Ronac Mamtani; Daniel Lee |
Urologic Oncology
|
|
Comparison of the ‘iROC’ trial participants to patients with bladder cancer in the United States undergoing radical cystectomy
|
December 22, 2022
|
PC3I Authors Daniel Lee; Ronac Mamtani |
BJU International
|
|
Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot study
|
February 23, 2023
|
PC3I Authors Ronac Mamtani |
BJUI Compass
|
|
Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
|
February 23, 2023
|
PC3I Authors Ramy Sedhom; Ronac Mamtani |
JAMA Oncology
|
|
Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
|
March 2, 2023
|
PC3I Authors Ronac Mamtani |
Journal of Cancer Research & Clinical Oncology
|
|
Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90
|
March 19, 2023
|
PC3I Authors Ronac Mamtani; Melina Marmarelis |
Clinical Lung Cancer
|
|
Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer
|
April 14, 2023
|
PC3I Authors Ronac Mamtani |
JAMA Network Open
|
|
Inverse Probability of Treatment Weighting and Confounder Missingness in Electronic Health Record-based Analyses: A Comparison of Approaches Using Plasmode Simulation
|
May 8, 2023
|
PC3I Authors Ronac Mamtani |
Epidemiology
|
|
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer
|
June 4, 2023
|
PC3I Authors Charu Aggarwal; Melina Marmarelis; Ronac Mamtani |
JAMA Oncology
|
|
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens
|
July 14, 2023
|
PC3I Authors Charu Aggarwal; Christopher A. D’Avella; Ronac Mamtani; Melina Marmarelis |
Clinical Lung Cancer
|
|
Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma
|
September 4, 2023
|
PC3I Authors Ronac Mamtani |
Cancer Investigation
|
|
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
|
October 2, 2023
|
PC3I Authors Ronac Mamtani |
Nature Medicine
|
|
Comparing survival in trial- versus routine-care advanced urothelial cancer patients on immune checkpoint blockade
|
April 29, 2024
|
PC3I Authors Lucy Wang; Ronac Mamtani |
Pharmacoepidemiology and Drug Safety
|
|
Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma
|
October 18, 2023
|
PC3I Authors Ronac Mamtani |
Frontiers in Oncology
|
|
Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer
|
March 19, 2024
|
PC3I Authors Ronac Mamtani |
Urologic Oncology
|
|
The association between telemedicine, advance care planning, and unplanned hospitalizations among high-risk patients with cancer
|
November 21, 2023
|
PC3I Authors Peter Gabriel; Ronac Mamtani |
Cancer
|
|
A clinical prediction model to assess risk for pancreatic cancer among patients with prediabetes
|
January 20, 2021
|
PC3I Authors Ronac Mamtani |
European Journal of Gastroenterology & Hepatology
|
|
Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival
|
November 27, 2023
|
PC3I Authors Ronac Mamtani |
JAMA Network Open
|
|
SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy
|
June 16, 2021
|
PC3I Authors Peter Gabriel; Ronac Mamtani |
JCO Oncology Practice
|
|
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
|
January 19, 2024
|
PC3I Authors Ronac Mamtani |
Nature Medicine
|
